4.3.1 Sintesi e raccomandazioni - Biblioteca Medica

3. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman
EB; Prospective European Doxazosin and Combination Therapy Study Investigators:
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in
treatment of symptomatic benign prostatic hyperplasia: the Prospective European
Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003 Jan; 61(1):
119-26.
4. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM.
Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-
year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy
Canadian Two year Study. CMAJ. 1996 Nov 1;155(9):1251-9.
5. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia:
a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Urology. 1998 May; 51(5): 677-86.
6. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD,
Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A,
Binkowitz B, Ng J; Finasteride Study Group. The effect of finasteride in men with
benign prostatic hyperplasia. J Urol. 2002 Feb; 167(2 Pt 2): 1102-7.
7. Hudson PB, Boake R, Trachtenberg J, Romas NA, Rosenblatt S, Narayan P, Geller J, Lieber
MM, Elhilali M, Norman R, Patterson L, Perreault JP, Malek GH, Bruskewitz RC, Roy
JB, Ko A, Jacobsen CA, Stoner E. Efficacy of finasteride is maintained in patients with
benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study
Group. Urology. 1999 Apr; 53(4): 690-5.
8. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller
J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN,
Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J; Finasteride Study Group.
Long-term 6-year experience with finasteride in patients with benign prostatic
hyperplasia. Urology. 2003 Apr; 61(4): 791-6.
9. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW,
Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP,
Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ,
Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical
Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of
doxazosin, finasteride, and combination therapy on the clinical progression of benign
prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387-98
10. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C,
Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign
prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia
Study Group. N Engl J Med. 1996 Aug 22;335(8):533-9.
11. Guideline on the Management of Benign Prostatic Hyperplasia. AUA Practice Guidelines
2003: Sito internet AUA: http://www.auanet.org/timssnet/products/guidelines/
bph_management.cfm. Accesso il 09 Giugno 2003.
12. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A,
Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J. Serum prostatespecific
antigen and prostate volume predict long-term changes in symptoms and flow
166